Seizure · 2026
Cannabidiol inhibits phenytoin clearance and can result in clinical changes: Two cases.
СтатьяКлинический случайНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Blond Benjamin N, Cardoza Candace, Mattson Richard H
Аннотация
PURPOSE: Cannabidiol has well described drug interactions including inhibition of clobazam metabolism. Phenytoin is known to induce metabolism of cannabidiol. Cannabidiol inhibition of phenytoin metabolism is predicted but not well described.
METHODS: We present the cases of two individuals with Lennox Gastaut Syndrome which demonstrate the clinical relevance of cannabidiol inhibition of phenytoin metabolism.
RESULTS: In the first case, the addition of cannabidiol led to increased levels of phenytoin and clobazam which resulted in freedom from previously refractory tonic-clonic seizures. This was sustained for one year. The phenytoin dose was later lowered due to concern for liver function and this led to recurrent seizures despite continued elevation of N-desmethylclobazam levels, suggesting the higher phenytoin was responsible for the seizure control. In the second case, the addition of cannabidiol led to phenytoin toxicity with ataxia and falls. Lowering phenytoin dose led to resolution of these symptoms.
CONCLUSION: Physicians should be aware of the interactions between phenytoin and cannabidiol in the management of epilepsy.
METHODS: We present the cases of two individuals with Lennox Gastaut Syndrome which demonstrate the clinical relevance of cannabidiol inhibition of phenytoin metabolism.
RESULTS: In the first case, the addition of cannabidiol led to increased levels of phenytoin and clobazam which resulted in freedom from previously refractory tonic-clonic seizures. This was sustained for one year. The phenytoin dose was later lowered due to concern for liver function and this led to recurrent seizures despite continued elevation of N-desmethylclobazam levels, suggesting the higher phenytoin was responsible for the seizure control. In the second case, the addition of cannabidiol led to phenytoin toxicity with ataxia and falls. Lowering phenytoin dose led to resolution of these symptoms.
CONCLUSION: Physicians should be aware of the interactions between phenytoin and cannabidiol in the management of epilepsy.